Fact Source: Financial Supervisory Service DART / 2026-01-21
Disclosure Type: Change in Revenue or Profit Structure of Over 30% (15% for Large-Scale Corporations)
💡 3-Second Summary
Samsung Biologics’ consolidated operating profit for the current fiscal year reached approximately KRW 2.07T, marking a 56.6% surge compared to the prior fiscal year. Continuous stable operations at Plants 1–3 and the increased revenue contribution from the full utilization of Plant 4 served as the primary drivers behind this financial growth.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Consolidated Profit/Loss Structure Changes (Unit: KRW / %):
- Revenue: Current FY KRW 4,556,971,695,000 (Prior FY KRW 3,497,145,676,000) | Growth Rate: +30.3%
- Operating Profit: Current FY KRW 2,069,221,267,000 (Prior FY KRW 1,321,366,381,000) | Growth Rate: +56.6%
- Profit Before Income Tax: Current FY KRW 2,118,631,253,000 (Prior FY KRW 1,384,868,830,000) | Growth Rate: +53.0%
- Net Income: Current FY KRW 1,614,330,309,000 (Prior FY KRW 1,040,301,541,000) | Growth Rate: +55.2%
- Primary Drivers for Performance Changes: Sustained stable operation of Plants 1–3, alongside increased revenue contributions driven by full-capacity utilization at Plant 4.
- Consolidated Financial Position (Unit: KRW):
- Total Assets: Current FY KRW 11,060,741,977,000 (Prior FY KRW 17,336,296,350,000)
- Total Liabilities: Current FY KRW 3,609,631,329,000 (Prior FY KRW 6,431,620,287,000)
- Total Equity: Current FY KRW 7,451,110,648,000 (Prior FY KRW 10,904,676,062,018)
- Capital Stock: Current FY KRW 115,727,378,000 (Prior FY KRW 177,935,000,000)
- Spin-off Related Specific Details:
- The stated figures for both the current and prior fiscal years exclude the discontinued operations income (net profit) of Samsung Bioepis caused by the corporate spin-off (Discontinued operations profit: KRW 43B in 2024 / KRW 170B in 2025).
- The balance sheet metrics for the current fiscal year exclude Samsung Bioepis data, whereas the prior fiscal year’s indicators represent the pre-spin-off structure and thus include Bioepis figures.
- Board Resolution: Resolved on 2026-01-21 with all 4 independent directors present (0 absent).
- Investor Notice: These results represent preliminary closing data compiled before the completion of the external auditor’s review. Figures are subject to change and investors must verify the subsequent “Submission of Audit Report” disclosure.
📈 2. [Expert View: What This Disclosure Means for Investors]
This regulatory filing stands as a vital fundamental milestone proving that Samsung Biologics has successfully expanded its operational scale and enhanced profitability as its major asset, Plant 4, reached full-scale operation. While consolidated revenue grew by 30.3%, operating profit outpaced it with a 56.6% increase, illustrating a strong margin expansion effect driven by higher factory utilization cutting down fixed cost ratios within its core CDMO framework.
However, investors will notice that total assets, liabilities, equity, and capital stock metrics all experienced numerical declines compared to the prior year. This reduction does not point to financial distress or capital impairment; rather, it reflects a structural accounting realignment due to the corporate spin-off. Because Samsung Bioepis details are excluded from the current fiscal year’s balance sheet while being retained in the previous year’s figures, a base effect distortion appears. Since minor data reclassifications remain possible during the final audit process, global investors should look past the apparent contraction in asset size and focus on the verified operating profit traction while tracking the upcoming statutory audit report for final validation.
📝 Editor’s Comment (by K-STOCK Editor)
Samsung Biologics’ latest earnings structure disclosure provides a textbook example of how massive capital expenditure deployment translates into earnings acceleration once production capacity peaks. Delivering an operating profit growth rate (56.6%) that significantly outdistances revenue expansion (30.3%) indicates that manufacturing efficiencies at Plant 4 have reached a highly lucrative operational phase. The apparent contraction in total asset and equity scales is a technical byproduct of the corporate spin-off process, which carved out Samsung Bioepis accounting lines from the current ledger, and carries zero connection to genuine structural risk. Given that these preliminary figures are unaudited, investors should maintain a balanced perspective and await the official audit report prior to the general shareholders’ meeting to cross-check the definitive metrics.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
